Best for 0% commission stocks
Capital at risk. Fees apply.
Copy picks from top traders
Commission-free trades
Fractional shares
Get dividend payments
Fractional shares
Get dividend payments
On December 30 2020 the Oxford-AstraZeneca vaccine was approved for use in the UK. There will be more than 500,000 doses available and the vaccine is easier to store and distribute than the Pfizer-BioNTech vaccine.
This will, no doubt, have an impact on the share price of the company. Investors are likely to buy shares with the hope that the share price of AstraZeneca will rise following this news and the hope that the vaccine will be approved for use in other countries worldwide.
How to buy shares in AstraZeneca
- Open a brokerage account. Choose from our top broker picks or compare brokers in depth. Then, complete an application.
- Fund your account. Add money to your account via bank transfer, debit card or credit card.
- Search the platform by ticker symbol. AZN in this case.
- Choose an order type. Place a market order or limit order with your preferred number of shares or dollar amount.
- Submit the order. It's that simple.
Our top picks for where to buy AstraZeneca shares
Best for fractional shares
Capital at risk. T&Cs apply.
Earn 5% on uninvested funds
Commission-free trades
Fractional shares
5,400+ stocks/ETFs
Fractional shares
5,400+ stocks/ETFs
Best for customer satisfaction
Capital at risk. T&Cs apply.
97% would recommend
Free fund trading
Expert insights
Wide range of accounts
Expert insights
Wide range of accounts
Fees calculator for buying AstraZeneca shares with popular apps
Both exchange rates and share prices fluctuate in real time, so the costs estimated here should be considered as a guide only. They don't factor in spreads, which can be hard to pin down. Always refer to the platform itself for availability and pricing.
Quantity of shares
1000
| Platform | Finder Score | Account fee | Min. initial deposit | Trade cost | Link |
|---|---|---|---|---|---|
|
4.3 ★★★★★ |
£0 | $100 | £111.38 |
Go to siteCapital at risk
|
 |
4.4 ★★★★★ |
£0 | £1 | £110.55 |
Go to siteCapital at risk
|
 |
4.7 ★★★★★ |
£0 | £1 | £110.55 |
Go to siteCapital at risk
|
|
4.4 ★★★★★ |
£0 | £0 | £110.55 |
Go to siteCapital at risk
|
|
4.2 ★★★★★ |
£0 | £1 | £122.50 |
Go to siteCapital at risk
|
 |
4.4 ★★★★★ |
0% - 0.25% | £100 | £110.55 |
Go to siteCapital at risk
|
Full comparison of share dealing platforms
These providers cover a wide range of stocks, but we can't guarantee they'll all offer this stock.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Alternative ways to invest in AstraZeneca
Buying shares in just one company is generally considered a riskier bet than investing in a range of investments - AKA a "diversified portfolio". Experts generally recommend holding a mix of investments in specific assets and funds. Funds are ready-made portfolios of multiple companies' shares (potentially including AstraZeneca), and the idea is that drops in the value of one constituent company's share price might be offset by rises in others.
AstraZeneca is a major part of the London stock exchange, so it's included in many global funds and investment trusts, as well as tracker-style exchange traded funds (ETFs).
| Fund | Icon | 5-year performance (to August 2024) | 1-year performance (to August 2024) | Link to invest |
|---|---|---|---|---|
| Xtrackers FTSE 100 (XDUK) |  | 31.44% | 10.09% | Invest with HLCapital at risk |
| iShares Core FTSE 100 (CUKX) |  | 31.39% | 9.60% | Invest with eToroCapital at risk |
| Invesco FTSE 100 (S100) |  | 30.75% | 9.76% | Invest with HLCapital at risk |
| HSBC FTSE 100 (HUKX) |  | 11.99% | 6.09% | Invest with XTBCapital at risk |
| Amundi FTSE 100 (100D) |  | 11.93% | 5.35% | Invest with HLCapital at risk |
| iShares Core FTSE 100 (Dist)(ISF) | | 8.14% | 5.57% | Invest with XTBCapital at risk |
| Vanguard FTSE 100 (VUKE) |  | 8.07% | 5.67% | Invest with XTBCapital at risk |
| 1 week (2024-10-21) | -99.91% |
|---|---|
| 1 month (2024-09-28) | -99.90% |
| 3 months (2024-07-28) | -99.91% |
| 6 months (2024-04-28) | -99.91% |
| 1 year (2023-10-28) | -99.89% |
| 2 years (2022-10-28) | -99.88% |
| 3 years (2021-10-28) | -99.87% |
| 5 years (2019-10-28) | -99.83% |
The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Invest in AstraZeneca shares
Finder Award
- Start investing from $50
- Pay no stamp duty on UK shares
- Commission-free trading. Other fees may apply.
Go to site
Capital at risk
Other fees may apply
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is AstraZeneca under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the AstraZeneca P/E ratio, PEG ratio and EBITDA.
AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, AstraZeneca's shares trade at around 37x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the United Kingdom stock market as of 09 November, 2023 (10). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, AstraZeneca's P/E ratio is best considered in relation to those of others within the industry or those of similar companies.
- Pfizer (PFE.US): 0.00
- Gilead Sciences (GILD.US): 106.96
- Johnson-and-Johnson (JNJ.US): 27.42
- Abbott Laboratories (ABT.US): 35.64
- IDEXX Laboratories (IDXX.US): 44.91
- GlaxoSmithKline (GSK.LSE): 12.92
AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8691. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider AstraZeneca's PEG ratio in relation to those of similar companies.
- Pfizer (PFE.US): 0.22
- Gilead Sciences (GILD.US): 0.51
- Johnson-and-Johnson (JNJ.US): 0.99
- Abbott Laboratories (ABT.US): 2.27
- IDEXX Laboratories (IDXX.US): 4.82
- GlaxoSmithKline (GSK.LSE): 0.80
AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £0 billion (£0 billion).
The EBITDA is a measure of AstraZeneca's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
- Pfizer (PFE.US): USD$10 billion
- Gilead Sciences (GILD.US): USD$13.5 billion
- Johnson-and-Johnson (JNJ.US): USD$30.1 billion
- Abbott Laboratories (ABT.US): USD$10.6 billion
- IDEXX Laboratories (IDXX.US): USD$1.3 billion
- GlaxoSmithKline (GSK.LSE): £11 billion
Frequently asked questions
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ready to compare platforms?More resources on Finder
More guides on Finder
-
How to buy Canopy Growth shares
Ever wondered how to buy shares in Canopy Growth? We explain how and compare a range of providers that can give you access to many brands, including Canopy Growth.
-
How to buy Green Thumb Industries shares
Ever wondered how to buy shares in Green Thumb Industries? We explain how and compare a range of providers that can give you access to many brands, including Green Thumb Industries.
-
How to buy Curaleaf Holdings shares
Ever wondered how to buy shares in Curaleaf Holdings? We explain how and compare a range of providers that can give you access to many brands, including Curaleaf Holdings.
-
How to buy Genesis Healthcare shares
Ever wondered how to buy shares in Genesis Healthcare? We explain how and compare a range of providers that can give you access to many brands, including Genesis Healthcare.
-
How to buy Allergy Therapeutics shares
Ever wondered how to buy shares in Allergy Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Allergy Therapeutics.
-
How to buy 4D pharma shares
Ever wondered how to buy shares in 4D pharma? We explain how and compare a range of providers that can give you access to many brands, including 4D pharma.
-
How to buy Aurora Cannabis shares
Ever wondered how to buy shares in Aurora Cannabis? We explain how and compare a range of providers that can give you access to many brands, including Aurora Cannabis.
-
How to buy Evgen Pharma shares
Thinking about buying shares in Evgen Pharma? We explain how to do it and compare a range of providers who will give you access to global markets.
-
How to buy Intuitive Surgical shares
Ever wondered how to buy shares in Intuitive Surgical? We explain how and compare a range of providers that can give you access to many brands, including Intuitive Surgical.
-
How to buy Stryker Corporation shares
Ever wondered how to buy shares in Stryker? We explain how and compare a range of providers that can give you access to many brands, including Stryker.